Insulin resistance and inflammation in the early phase of type 2 diabetes: Potential for therapeutic intervention

Scandinavian Journal of Clinical and Laboratory Investigation, Supplement

Volumn 65, Issue 240, 2005, Pages 30-40

  Schernthaner, Gerit Holger ^a   Schernthaner, Guntram ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

Adiponectin; Glitazones; Insulin resistance; Metabolic Syndrome; Prediabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ADIPOCYTOKINE; ADIPONECTIN; FATTY ACID; INSULIN SENSITIZING AGENT; INTERLEUKIN 6; LEPTIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SIGNAL PEPTIDE;

ADIPOSE TISSUE; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; DIET THERAPY; DISEASE COURSE; DISEASE DURATION; EDEMA; ENDOTHELIUM; EXERCISE; GLUCOSE INTOLERANCE; HEART FAILURE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LONGITUDINAL STUDY; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; WEIGHT REDUCTION; DIABETIC ANGIOPATHY; DIET; DISEASE ASSOCIATION; DISEASE EXACERBATION; ENDOTHELIAL DYSFUNCTION; FLUID RETENTION; SIDE EFFECT; WEIGHT GAIN; BLOOD; PHYSIOLOGY; REVIEW;

ADIPONECTIN; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; METABOLIC SYNDROME X; OBESITY; PPAR ALPHA; THIAZOLIDINEDIONES;

EID: 23744441515     PISSN: 0085591X     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365510500236119     Document Type: Conference Paper

References (75)

1. King, H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21:1414-1431
2. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24:683-689
3. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607
4. Kylin E: Studien über das Hypertonie-Hyperglykamie- Hyperurikamiesyndrom. Zentralblatt für Innere Medizin 1923; 44:105-127
5. Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998; 47:1643-1649
6. Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the "metabolic syndrome" and incidence of type 2 diabetes. Diabetes 2002; 51:3120-3127
7. Pereira MA, Kartashov AI, Ebbeling CB, Van Horn L, Slattery ML, Jacobs DR Jr, Ludwig DS. Fast-food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis. Lancet 2005; 365:36-42
8. Dunstan DW, Zimmet PZ, Welborn TA, et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002; 25:829-834
9. Accili D. Perspectives in Diabetes. The Struggle for Mastery in Insulin Action: From Triumvirate to Republic. Diabetes 2004; 53:1633-1642
10. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and IL-6 with metabolic syndrome X. Diabetologia 1997;40:1286-1292
11. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001; 286:327-334
12. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342:836-843
13. Han TS, Sattar N, Williams K, et al. Prospective study of reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 25:2016-2021
14. Freeman DJ, Norrie J, Caslake MJ, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002; 51:1596-1600
15. Duncan BB, Schmidt MI, Pankow JS, et al. Low-grade systemic inflammation and the development of type 2 diabetes. Diabetes 2003; 52:1799-1805
16. Verma S, Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function. Circulation 2004; 109:2058-2067
17. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109:2818-2825
18. The Diabetes Prevention Program Research Group. Prevention of Type 2 Diabetes with Troglitazone in the Diabetes Prevention Program. Diabetes 2005; 54:1150-1156
19. Schernthaner G. Cardiovascular mortality and morbidity in type-2 diabetes mellitus. Diabetes Research and Clinical Practise 1996; 31 Suppl S3-S13
20. Haffner SM, Mykkanen L, Festa A, et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000; 101:975-980
21. Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome. Circulation 2000; 102:42-47
22. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106:679-684
23. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25:4-7
24. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003; 24:278-301
25. Sjöholm, A, Nyström T. Endothelial inflammation in insulin resistance. Lancet 2005; 365:610-612
26. Devaraj S, Rosenson RS, Jialal I. Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am. 2004; 33:431-453
27. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004; 92:347-355
28. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocytederived plasma protein, inhibits endothelial NF-kB signaling through a cAMP-dependent pathway. Circulation 2000; 102:1296-1301
29. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20:1595-1599
30. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86:1930-1935
31. Duncan BB, Schmidt MI, Pankow JS et al. Adiponectin and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes 2004; 53:2473-2478
32. Lindsay RS, Funahashi T, Hanson RL, et al.Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360:57-58
33. Snehalatha C, Mukesh B, Simon M, et al. Plasma adiponectin is an independent predictor of type 2 diabetes in Asian indians. Diabetes Care 2003; 26:3226-3229
34. Spranger J, Kroke A, Mohlig M et al: Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361:226-228
35. Krakoff J, Funahashi T, Stehouwer CD et al. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 2003; 26:1745-1751
36. Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002; 51:2968-2974
37. Kang ES, Park SY, Kim HJ, Ahn, CW, Nam M, Cha BS, Lim SK, Kim KR, and Lee, HC. The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes. Diabetes Care 2005; 28:1139-1144
38. Debril MB, Renaud JP, Fajas L, et al. The pleiotropic functions of peroxisome proliferator-activated receptor. J Mol Med 2001; 79:30-47
39. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20:649-688
40. Yoshimoto T, Naruse M, Nishikawa M. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol. 1997; 272:E989-E996
41. Smith U. Thiazolidinedione-induced effects beyond glycaemic control. Br J Diabetes Vasc Dis. 2002; 2 (suppl 1):S24-S27
42. Bennett SM, Agrawal A, Elasha H, Heise M, Jones NP, Walker M, Wilding JP. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet Med. 2004; 21:415-422
43. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med. 2004; 164:2097-2104
44. Langenfeld MR, Forst T, Hohberg C, Kann P, Lubben G, Konrad T, Fullert SD, Sachara C, Pfutzner A. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005; 111:2525-2531
45. Choi D, Kim SK, Choi SH, Ko YG, Ahn CW, Jang Y, Lim SK, Lee HC, Cha BS. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004; 27:2654-60
46. Reaven GM. The Insulin Resistance Syndrome: Definition and Dietary Approaches to Treatment. Annu Rev Nutr. 2005; 25:17.1-17.16
47. Hu G, Jousilahti P, Barengo NC, Qiao Q, Lakka TA, Tuomilehto J. Physical activity, cardiovascular risk factors, and mortality among Finnish adults with diabetes. Diabetes Care 2005; 28:799-805
48. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P; Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab. 2004; 89:6068-6076
49. Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med. 2005; 22:399-405
50. Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH; One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004; 27:141-147
51. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev. 2005; 21:167-174
52. Ceriello A, Johns D, Widel M, Eckland DJ, Gilmore KJ, Tan MH. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care 2005; 28:266-272
53. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002; 87:2784-2791
54. Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003; 52:1364-1370
55. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004; 53:2169-2176
56. Retnakaran R, Hanley AJ, Raif N, Hirning CR, Connelly PW, Sermer M, Kahn SE, Zinman B. Adiponectin and beta cell dysfunction in gestational diabetes: pathophysiological implications Diabetologia 2005; 48:993-1001
57. Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH, Hanefeld M. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005 (in press)
58. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004; 27:256-263
59. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005; 111:583-590
60. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37:917-923
61. Belcher G, Schernthaner G. Changes in liver tests during one-year treatment of patients with type 2 diabetes with pioglitazone, metformin, or gliclazide. Diabetic Medicine 2005 (in press)
62. Charbonnel B, Dormandy J. Erdmann E, Massi-Benedetti M, Skene A; PROactive Study Group. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004; 27:1647-1653
63. Schernthaner G. Progress in the prevention of type 2 Diabetes. Wien.Klin.Wochenschr. 2003; 115:745-757
64. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20:537-544
65. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of type-2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343-1350
66. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403
67. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, et al. Acarbose for prevention of type-2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359:2072-2077
68. Hensrud DD. Dietary treatment and long-term weight loss and maintenance in type 2 diabetes. Obes Res. 2001; Suppl 4:348S-353S
69. Sjostrom L, Lindroos AK, Peltonen M, et al. Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004; 351:2683-2693
70. Buchwald H, Avidor Y, Braunwald E, et a. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292:1724-1737
71. Kopp HP, Kopp CW, Festa A, et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol. 2003; 23:1042-7
72. Christou NV, Sampalis JS, Liberman M, et al. Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg. 2004; 240:416-23
73. Kopp CW, Kopp HP, Steiner S, et al. Weight loss reduces tissue factor in morbidly obese patients. Obes Res. 2003; 11:950-956
74. Krzyzanowska K, Mittermayer F, Kopp HP, et al. Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women. J Clin Endocrinol. Metab. 2004; 89:6277-6281
75. Kopp HP, Spranger J, Möhlig M, Krzyzanowska K, Pfeiffer A.F.H, Schernthaner G Effect of weight loss on plasma levels of adiponectin in association with markers of chronic subclinical inflammation and the insulin resistance syndrome in obese subjects. Internat. J. Obes. 2005 (in press)